- Home
- NTZ vs MAIA Comparison
NTZ vs MAIA Comparison
Compare NTZ & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTZ
- MAIA
- Stock Information
- Founded
- NTZ 1959
- MAIA 2018
- Country
- NTZ Italy
- MAIA United States
- Employees
- NTZ N/A
- MAIA N/A
- Industry
- NTZ Home Furnishings
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- NTZ Consumer Discretionary
- MAIA Health Care
- Exchange
- NTZ Nasdaq
- MAIA Nasdaq
- Market Cap
- NTZ 41.6M
- MAIA 46.7M
- IPO Year
- NTZ 1993
- MAIA 2022
- Fundamental
- Price
- NTZ $3.25
- MAIA $1.88
- Analyst Decision
- NTZ
- MAIA
- Analyst Count
- NTZ 0
- MAIA 0
- Target Price
- NTZ N/A
- MAIA N/A
- AVG Volume (30 Days)
- NTZ 1.8K
- MAIA 529.1K
- Earning Date
- NTZ 07-02-2025
- MAIA 08-08-2025
- Dividend Yield
- NTZ N/A
- MAIA N/A
- EPS Growth
- NTZ N/A
- MAIA N/A
- EPS
- NTZ N/A
- MAIA N/A
- Revenue
- NTZ $337,653,480.00
- MAIA N/A
- Revenue This Year
- NTZ N/A
- MAIA N/A
- Revenue Next Year
- NTZ N/A
- MAIA N/A
- P/E Ratio
- NTZ N/A
- MAIA N/A
- Revenue Growth
- NTZ N/A
- MAIA N/A
- 52 Week Low
- NTZ $3.04
- MAIA $1.40
- 52 Week High
- NTZ $6.27
- MAIA $4.24
- Technical
- Relative Strength Index (RSI)
- NTZ 31.63
- MAIA 56.41
- Support Level
- NTZ $3.25
- MAIA $1.80
- Resistance Level
- NTZ $3.32
- MAIA $2.15
- Average True Range (ATR)
- NTZ 0.05
- MAIA 0.13
- MACD
- NTZ -0.06
- MAIA 0.02
- Stochastic Oscillator
- NTZ 0.00
- MAIA 60.00
About NTZ Natuzzi S.p.A.
Natuzzi SpA is an Italian firm that designs, manufactures, and sells contemporary and traditional leather and fabric-upholstered furniture. Its product portfolio includes sofas, loveseats, armchairs, sectional furniture, motion furniture and sofa beds, living room furnishings, and accessories. The company markets its products under several brands such as Natuzzi Italia, Private label, and Natuzzi Editions. Geographically, it derives a majority of its revenue from the United States of America and also has an international presence in Italy, Spain, the UK, China, and Other countries.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.